Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574470 · ClinicalTrials.gov registry record · Phase 4
Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT00574470 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 3 participants.
The verdict
NCT00574470, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab. We hypothesize that a combination of daclizumab and infliximab will more effectively treat graft versus host disease than therapy with a single drug. The study also looks at whether chronic graft versus host disease develops, and survival at 6 and 9 months post-treatment.
Interventions
- DRUG daclizumab, infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574470
The ClinicalTrials.gov registry entry for NCT00574470 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which daclizumab, infliximab is the first listed.
NCT00574470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574470 about?
NCT00574470 is a clinical study titled "Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD". The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab. We hypothesize that a combination of daclizumab and infliximab will more effectively treat graft versu...
What is the current status of trial NCT00574470?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2006-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00574470?
The interventions under investigation include: daclizumab, infliximab (DRUG).
Who is sponsoring clinical trial NCT00574470?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.